prikaz prve stranice dokumenta Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
  Preuzmi
PDF 7.88 MB
Znanstveni rad - Izvorni znanstveni rad
Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
Vaccines, 10 (2022), 2; 153. https://doi.org/10.3390/vaccines10020153
Đaković Rode, Oktavija; Bodulić, Kristian; Zember, Sanja; Cetinić Balent, Nataša; Novokmet, Anđa; Čulo, Marija; Rašić, Željka; Mikulić, Radojka; Markotić, Alemka

Povezani objekti
COVID-19 | Virtualna zbirka
Citirajte ovaj rad

Đaković Rode, O., Bodulić, K., Zember, S., Cetinić Balent, N., Novokmet, A., Čulo, M. ... Markotić, A. (2022). Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Vaccines, 10. (2). doi: 10.3390/vaccines10020153

Đaković Rode, Oktavija, et al. "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose." Vaccines, vol. 10, br. 2, 2022. https://doi.org/10.3390/vaccines10020153

Đaković Rode, Oktavija, Kristian Bodulić, Sanja Zember, Nataša Cetinić Balent, Anđa Novokmet, Marija Čulo, Željka Rašić, Radojka Mikulić i Alemka Markotić. "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose." Vaccines 10, br. 2 (2022). https://doi.org/10.3390/vaccines10020153

Đaković Rode, O., et al. (2022) 'Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose', Vaccines, 10(2). doi: 10.3390/vaccines10020153

Đaković Rode O, Bodulić K, Zember S, Cetinić Balent N, Novokmet A, Čulo M, i sur.. Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Vaccines [Internet]. 20.01.2022. [pristupljeno 19.11.2024.];10(2). doi: 10.3390/vaccines10020153

O. Đaković Rode, et al., "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose", Vaccines, vol. 10, br. 2, Siječanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:254996. [Citirano: 19.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:254996
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
AutorOktavija Đaković Rode
AutorKristian Bodulić
AutorSanja Zember
AutorNataša Cetinić Balent
AutorAnđa Novokmet
AutorMarija Čulo
AutorŽeljka Rašić
AutorRadojka Mikulić
AutorAlemka Markotić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Research on post-vaccination antibody dynamics has become pivotal in estimating COVID-19 vaccine efficacy. We studied anti-SARS-CoV-2 Spike RBD IgG levels in 587 healthcare workers (2038 sera) who completed BNT162b2 vaccination. Average antibody titer 3 weeks after the first dose in COVID-19-naïve participants (median 873.5 AU/mL) was 18-fold higher than the test threshold, with a significant increase 1 month (median 9927.2 AU/mL) and an exponential decrease 3 (median 2976.7 AU/mL) and 6 (median 966.0 AU/mL) months after complete vaccination. Participants with a history of COVID-19 prior to vaccination showed significantly higher antibody levels, particularly after the first dose (median 14,280.2 AU/mL), with a slight decline 1 month (median 12,700.0 AU/mL) and an exponential decline in antibody titers 3 (median 4831.0 AU/mL) and 6 (median 1465.2 AU/mL) months after vaccination. Antibody levels of COVID-19-naïve subjects after the first dose were moderately correlated with age (r = −0.4). Multivariate analysis showed a strong independent correlation between IgG levels 6 months after vaccination and both IgG titers after the first dose and 1 month after vaccination (R2 = 0.709). Regardless of pre-vaccination COVID-19 history, IgG levels 6 months after vaccination were comparable to antibody levels reached by COVID-19-naïve participants after the first vaccine dose.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaVaccines
Brojčani podacivol. 10, br. 2, 153
e-ISSN2076-393X
DOIhttps://doi.org/10.3390/vaccines10020153
URN:NBNurn:nbn:hr:184:254996
Datum objave publikacije2022-01-20
ProjektŠifra: KK.011.1.01.0006
Naziv (hrvatski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: eu
Financijer: ERDF
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttps://www.mdpi.com/2076-393X/10/2/153
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-03-16 22:35:20